Impact of Dexamethasone on COVID-19 Patients
Authors: Widad M. Al-Bishri(1),
Ghadeer H. Alhazmi (2),
Barah M. Sulaiman (3),
Duaa M. Mandeeli (4),
Bashayer F. AlSulaymani (5),
Adyan k. Qurban (6)
Department of Biochemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia (1)
Bachelor of medical laboratory, Laboratory specialist in Maternity and Children Hospital, Makkah, Saudi Arabia (2,3.4),
Bachelor of genomics and biotechnology, Medical Laboratory Department, Collage of Applied Medical Science, University of Jeddah, Jeddah, Saudi Arabia (5),
Bachelor of pharmacy, Pharmacist, Bayer Consumer Health Care, Makkah, Saudi Arabia (6)
Email: MiSs.Ghadora@hotmail.com
Doi: doi.org/10.52132/Ajrsp.e.2022.34.2
The coronavirus infection 19 (COVID-19) is an extremely contagious as well as infectious
agent’s viral illness generated by the extreme acute respiratory disorder coronavirus which
called (SARS-CoV-2) virus, which first appeared in Wuhan as well as China, and has since
spread throughout the world. The 2019 Coronavirus Infection (COVID-19) is linked to diffuse
lung injury. Corticosteroids can help to prevent respiratory damage as well as death by
modulating inflammation injury occurs in the lung. The aim of this literature review is
to obtain a knowledge of current studies as well as debates related to this specific
research subject, as well as the objectives of this research were to look at the
anti-inflammatory effects of corticosteroids (particularly dexamethasone)
in individuals with COVID-19-induced moderate-to-severe Acute respiratory
distress syndrome (ARDS). It also described the pathway of glucocorticoid
metabolic effects as well as illustrated some adverse effects of dexamethasone
on various organs in COVID-19 patients. According to the findings,
small quantities of corticosteroids (dexamethasone) can minimize
mortality with serious COVID-19 disorder.
Coronavirus, Dexamethasone, Corticosteroids, Respiratory viruses, Treated
Download PDF
Academic Journal of Research and Scientific Publishing